Abstract
BackgroundAfter a preliminary study demonstrated its feasibility, a new Central IntraVenous Additive Service (CIVAS) opened in April 2016 dedicated to the compounding of non-toxic injectable drugs (IV) in a new...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have